Analyzing Dynatronics Corporation (DYNT) and Neovasc (NVCN)
Dynatronics Corporation (NASDAQ: DYNT) and Neovasc (NASDAQ:NVCN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.
This is a summary of current ratings and recommmendations for Dynatronics Corporation and Neovasc, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Neovasc has a consensus target price of $6.33, suggesting a potential upside of 266.09%. Given Neovasc’s higher possible upside, analysts plainly believe Neovasc is more favorable than Dynatronics Corporation.
Institutional and Insider Ownership
18.2% of Dynatronics Corporation shares are held by institutional investors. Comparatively, 19.6% of Neovasc shares are held by institutional investors. 63.9% of Dynatronics Corporation shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Dynatronics Corporation has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Neovasc has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.
This table compares Dynatronics Corporation and Neovasc’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Dynatronics Corporation and Neovasc’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Dynatronics Corporation||$32.72 million||0.28||-$261,530.00||($1.05)||-2.38|
|Neovasc||$8.58 million||15.91||-$23.14 million||($0.14)||-12.36|
Dynatronics Corporation has higher revenue and earnings than Neovasc. Neovasc is trading at a lower price-to-earnings ratio than Dynatronics Corporation, indicating that it is currently the more affordable of the two stocks.
Neovasc beats Dynatronics Corporation on 7 of the 12 factors compared between the two stocks.
About Dynatronics Corporation
Dynatronics Corporation is a manufacturer and distributor of physical medicine products. The Company’s products include a line of medical equipment for physical medicine applications, including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. Its products are used by physical therapists, chiropractors, sports medicine practitioners, podiatrists, physicians and other physical medicine professionals. Its physical medicine products include therapeutic modalities, such as Dynatron Solaris, including electrotherapy and thermal therapy, and 25 Series, including electrotherapy and ultrasound; manufactured capital products, including traction systems and wood furniture; manufactured supplies, including cold packs, straps, wedges, bolsters and mats; distributed capital products, including hydrotherapy, weight training equipment and pilates, and distributed supplies, including clinical accessories, sports med and taping products, lotions and gels.
Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Receive News & Ratings for Dynatronics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynatronics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.